Synonyms:didanosine, 2',3'-Dideoxyinosine, 69655-05-6, DIDEOXYINOSINE, Videx, Videx EC, Inosine, 2',3'-dideoxy-, ddIno, Didanosinum, Didanosina, DDI, 2,3-dideoxyinosine, BMY-40900, (-)-didanosine, NSC-612049, K3GDH6OH08, DTXSID6022927, 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one, CHEBI:490877, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-ol, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one, NSC 612049, 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE, NCGC00090691-03, NCGC00159514-02, Didanosine 100 microg/mL in Acetonitrile, 9-((2R,5S)-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one, 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one, 2',3'-Dideoxyinosine (ddI), DTXCID402927, 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one, Hypoxanthine ddN, Didanosinum [INN-Latin], NSC612049, Didanosina [INN-Spanish], 9-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-6,9-DIHYDRO-3H-PURIN-6-ONE, D2I, SMR000058576, Videx(TM), Intron A & Videx, CAS-69655-05-6, Videx (TN), PC-SOD+ddI, Dideoxyinosine (DDI), LOA & ddI, ddI + d4T combination, ddI & GM-CSF, SR-05000001487, DRG-0016, DDI and rIFN.alpha.2, BMY 40900, ddI & sCD4(rsCD4), UNII-K3GDH6OH08, CCRIS 805, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one, DS-4152 & ddI, HSDB 6548, Didanosine,(S), Didanosine [USAN:USP:INN:BAN], Didanosine (DDI), 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine, Didanosine (Videx), Didanosine and Interferon-.alpha.-2, MFCD00077728, Videx EC(TM)(slow-release capsules), KS-1049, BRN 3619529, 2',3'-didesoxyinosin, 2',3'-Dideoxyinosine (AIDS Initiative), ddI & IFN-.alpha., DIDANOSINE [MI], DIDANOSINE [INN], DIDANOSINE [JAN], 2', 3'-dideoxyinosine, DIDANOSINE [HSDB], DIDANOSINE [USAN], DIDANOSINE [VANDF], DIDANOSINE [MART.], SCHEMBL3363, CHEMBL1460, DIDANOSINE [USP-RS], DIDANOSINE [WHO-DD], DIDANOSINE [WHO-IP], 9-(2,3-Dideoxy-beta-D-ribofuranosyl)hypoxanthine, Listera ovata agglutinin & 2',3'-Dideoxyinosine, Didanosine (JAN/USP/INN), MLS000759469, MLS001055350, MLS001424118, MLS002154216, MLS006011561, 3'-Azido-3'-deoxythymidine + 2',3'-Dideoxyinosine, GTPL4833, DIDANOSINE [EP IMPURITY], DIDANOSINE [ORANGE BOOK], Didanosine for system suitability, 2',3'-Dideoxyinosine & sCD4(soluble recombinant protein), DIDANOSINE [EP MONOGRAPH], DIDANOSINE [USP IMPURITY], DIDANOSINE [USP MONOGRAPH], HMS2051J11, HMS2089N20, HMS2095O08, HMS2232P22, HMS3712O08, HMS3884M06, DIDANOSINUM [WHO-IP LATIN], HY-B0249, Tox21_111732, Tox21_202333, Tox21_300575, 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-3H-purin-6-one, BDBM50404252, 2',3'-Dideoxyinosine & Granulocyte-macrophage colony-stimulating factor, 2',3'-DIDEOXYINOSINE; Didanosine, AKOS015833088, AKOS015901454, AKOS015963259, AKOS026750545, Tox21_111732_1, CCG-100947, CCG-220153, DB00900, NC00197, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,9-dihydro-6H-purin-6-one, SRI-7013-04, SRI-7013-05, SRI-7013_07, NCGC00090691-01, NCGC00090691-02, NCGC00090691-14, NCGC00159514-03, NCGC00159514-04, NCGC00164280-01, NCGC00188983-01, NCGC00254496-01, NCGC00259882-01, NCGC00390773-01, 2DI, AC-12026, AC-32186, BP-58651, SMR004703324, 2',3'-Dideoxyinosine, >=98% (HPLC), 2',3'-Dideoxyinosine & Interferon-.alpha., D3066, SW198619-2, 9-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran, C06953, D00296, EN300-123032, T71244, Q422606, J-700356, SR-05000001487-1, SR-05000001487-2, W-203551, Z1546616193, Didanosine, European Pharmacopoeia (EP) Reference Standard, Didanosine, United States Pharmacopeia (USP) Reference Standard, Inosine, 2',3'-dideoxy- & Recombinant Interferon-.alpha.-2, Lecithinized superoxide dismutase & Inosine, 2',3'-dideoxy-, 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol, 2 inverted exclamation mark ,3 inverted exclamation mark -Dideoxyinosine, 9-((2R,5S)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL)-1H-PURIN-6(9H)-ONE, Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard
Pubchem:PUBCHEM:50599
Id:9b9aa554-e6e4-5f16-a437-0c9cff9ce12c
Description:nan
